DNA vaccines were pioneered by several groups in the early 1990s. This article presents the reflections of one of these groups on their work with retroviral vectors in chickens that contributed to the discovery and early development of DNA vaccines. Although the findings were initially met with skepticism, the work presented here combined with that of others founded a new method of vaccination: the direct inoculation of purified DNA encoding the target antigen.
Get full access to this article
View all access options for this article.
References
1.
JennerE. An Inquiry into the Causes and Effects of the Variolae Vaccine. London: Sampson Low, 1798
2.
HardeeCL, Arevalo-SolizLM, HornsteinBD, et al.Advances in non-viral DNA vectors for gene therapy. Genes (Basel), 2017; 8:65.
3.
Tiptiri-KourpetiA, SpyridopoulouK, PappaA, et al.DNA vaccines to attack cancer: strategies for improving immunogenicity and efficacy. Pharmacol Ther, 2016; 165:32–49.
4.
LiuS, WangS, LuS. DNA immunization as a technology platform for monoclonal antibody induction. Emerg Microbes Infect, 2016; 5:e33.
5.
MackettM, SmithGL, MossB. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A, 1982; 79:7415–7419.
6.
PanicaliD, PaolettiE. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A, 1982; 79:4927–4931.
7.
HuntLA, BrownDW, RobinsonHL, et al.Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections. J Virol, 1988; 62:3014–3019.
8.
IsraelMA, ChanHW, HourihanSL, et al.Biological activity of polyoma viral DNA in mice and hamsters. J Virol, 1979; 29:990–996.
9.
HalpernMS, EwertDL, EnglandJM. Wing web or intravenous inoculation of chickens with v-src DNA induces visceral sarcomas. Virology, 1990; 175:328–331.
10.
ChristouP, McCabeDE, SwainWF. Stable transformation of soybean callus by DNA-coated gold particles. Plant Physiol, 1988; 87:671–674.
11.
WilliamsRS, JohnstonSA, RiedyM, et al.Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci U S A, 1991; 88:2726–2730.
12.
SanfordJC, SmithFD, RussellJA. Optimizing the biolistic process for different biological applications. Methods Enzymol, 1993; 217:483–509.
13.
TangDC, De VitM, JohnstonSA. Genetic immunization is a simple method for eliciting an immune response. Nature, 1992; 356:152–154.
14.
FynanEF, WebsterRG, FullerDH, et al.DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A, 1993; 90:11478–11482.
15.
WolffJA, MaloneRW, WilliamsP, et al.Direct gene transfer into mouse muscle in vivo. Science, 1990; 247:1465–1468.
16.
UlmerJB, DonnellyJJ, ParkerSE, et al.Heterologous protection against influenza by injection of DNA encoding a viral protein. Science, 1993; 259:1745–1749.
17.
WangB, UgenKE, SrikantanV, et al.Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences U S A, 1993; 90:4156–4160.
18.
DavisHL, MichelML, WhalenRG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet, 1993; 2:1847–1851.
19.
CalarotaS, BrattG, NordlundS, et al.Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet, 1998; 351:1320–1325.
20.
XiangZ, ErtlHC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity, 1995; 2:129–135.
21.
RobinsonHL, GinsbergHS, DavisHL, et al.The Scientific Future of DNA for Immunization. Washington, DC: American Academy of Microbiology, 1997.
22.
RobinsonHL, HuntLA, WebsterRG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine, 1993; 11:957–960.
SuschakJJ, WangS, FitzgeraldKA, et al.A cGAS-independent STING/IRF7 pathway mediates the immunogenicity of DNA vaccines. J Immunol, 2016; 196:310–316.
25.
HollisterK, ChenY, WangS, et al.The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination. Hum Vaccin Immunother, 2014; 10:1985–1992.
26.
SchneiderJ, GilbertSC, HannanCM, et al.Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev, 1999; 170:29–38.
27.
AmaraRR, VillingerF, AltmanND, et al.Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science, 2001; 292:69–74.
28.
RichmondJF, MustafaF, LuS, et al.Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology, 1997; 230:265–274.
29.
RichmondJF, LuS, SantoroJC, et al.Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol, 1998; 72:9092–9100.
30.
DowdKA, KoS-Y, MorabitoKM, et al.Rapid development of a DNA vaccine for Zika virus. Science, 2016; 354:237–240.
31.
ShedlockDJ, AvilesJ, TalbottKT, et al.Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther, 2013; 21:1432–1444.
32.
MuthumaniK, et al.A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med, 2015; 7:301ra132.
33.
GrahamBS, EnamaME, NasonMC, et al.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One, 2013; 8:e59340.
34.
FelgnerPL. Improvements in cationic liposomes for in vivo gene transfer. Hum Gene Ther, 1996; 7:1791–1793.
35.
SullivanSM, DoukasJ, HartikkaJ, et al.Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv, 2010; 7:1433–1446.
36.
WideraG, AustinM, RabussayD, et al.Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol, 2000; 164:4635–4640.
37.
ChapmanBS, ThayerRM, VincentKA, et al.Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucl Acids Res, 1991; 19:3979–3986.
38.
AndreS, SeedB, EberleJ, et al.Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol, 1998; 72:1497–1503.
39.
HoPP, FontouraP, PlattenM, et al.A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J Immunol, 2005; 175:6226–6234.
40.
KlinmanDM, YamshchikovG, IshigatsuboY. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol, 1997; 158:3635–3639.
41.
AshkarAA, RosenthalKL. Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med, 2002; 2:545–556.
42.
KimJJ, BagarazziML, TrivediN, et al.Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol, 1997; 15:641–646.
43.
GoepfertPA, ElizagaML, SatoA, et al.Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis, 2011; 203:610–619.
44.
GoepfertPA, et al.Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis, 2014; 210:99–110.
45.
BuchbinderSP, GrunenbergNA, SanchezBJ, et al.Immunogenicity of a novel Clade B HIV-1 vaccine combination: results of Phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS One, 2017; 12:e0179597.
